Clinical and sequencing data

Published: 31 July 2017| Version 1 | DOI: 10.17632/kcwswn7tdp.1
Catherine Coombs


Sheet 1 contains clinical data for the 5,649 patients included in the manuscript. Patients are numbered consecutively - sample1 through sample5649. MeanCoverage is coverage from blood sequencing. Presence/absence of mutations in top 5 recurrently mutated genes are depicted in addition to presence/absence of clonal hematopoiesis (CH) or clonal hematopoiesis in a presumptive driver (CH-PD). Additional clinically relevant variables include age at time of blood draw, gender, race, vital status, days to last follow up, prior exposure to chemotherapy and/or radiation therapy, laboratory parameters at time of blood sampling (including white blood cell cunt, hemoglobin, mean corpuscular volume, absolute neutrophil, lymphocyte and monocyte counts, platelet count, red-cell distribution width, record of prior blood transfusion (all), platelet transfusion (only), red blood cell transfusion (only), and prior receipt of growth factor. Sheet 2 contains mutation calls for all patients who were determined to have either CH. Of note is that for sample1-sample5649, only those patients from sheet 1 with CH were included on sheet 2. For sample5650 to sample6509, these are all patients with CH variants from the larger subset of sequenced patients (8,810 patients in total). This sheet includes mutated gene, and nomenclature for both cDNA and amino acid change, in addition to the variant allele frequency of the mutation in both the blood and the tumor tissue. Lastly it describes whether any given CH mutation is defined as a CH-PD mutation.



Memorial Sloan Kettering Cancer Center


Cancer Genetics, Hematopoietic Carcinogenesis, General Hematopoiesis, Malignant Hematopoiesis, Genetic Susceptibility to Cancer